Cytokinetics, Incorporated

NASDAQ:CYTK

Biotechnology

Healthcare
$51.32 +3.86%

+$2.90 today

Market cap
$7.15B
Beta
0.43
P/E (TTM)
-11.6
EPS (TTM)
-$6.73
52W Low $31.99High $80.20

Volume 1.59M

Average 2.37M

CYTK EBITDA Margin

EBITDA as a percentage of revenue.

Cytokinetics, IncorporatedNASDAQ: CYTK

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to -611.4%

EBITDA Margin was -611.4% in Q2 FY2026, down 449.9 pp from a year earlier. On a trailing-twelve-month basis it was -1158.1%, down 569.3 pp year over year. Over 3 fiscal years it narrowed by 529.1 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 15 analysts of -322.9% for the fiscal year ending Dec 2026, up from -880.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-611.4%+263.4 pp QoQ
Last fiscal yearDec 2025
-880.1%+1791.1 pp YoY
LTMJun 2026
-1158.1%-569.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-449.9 pp+13941.6 pp+14391.6 pp
1 year+1791.1 pp+557.2 pp-1233.9 pp
3 years-529.1 pp+870.9 pp+1400.1 pp
5 years+923.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-880.1%
Year-over-year change
+1791.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CYTK compares with its peers on the latest reported figures

  • CYTK's LTM Jun 2026 EBITDA Margin of -1158.1% is the 2nd highest of the 3 companies compared; the peer median is -16975.9%.
CYTK Competitors Peer median
EBITDA Margin for CYTK and competitors
Company Period LTM level YoY 3-year change
RNAAtrium Therapeutics, Inc.FY2025-410.9% ——
CYTKCytokinetics, IncorporatedLTM Jun 2026-1158.1% -569.3 pp-529.1 pp
TNYATenaya Therapeutics, Inc.LTM Mar 2026-33540.9% ——
KARDKardigan, Inc.—— ——
Peer median (excluding CYTK) -16975.9%——

Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue70.43M94.59M7.53M18.47M88.04M
Cost of Revenue159.94M240.81M330.12M339.41M10.13M
Gross Profit(89.51M)(146.23M)(322.59M)(320.93M)77.91M
Gross Margin-127.1%-154.6%-4284.1%-1737.2%88.5%
Research & Development159.94M240.81M330.12M339.41M405.9M
Selling, General & Admin96.8M177.98M173.61M215.31M284.27M
Operating Expenses96.8M177.98M173.61M215.31M690.17M
Depreciation & Amortization2.28M5.81M11.89M9.53M10.13M
EBITDA(183.71M)(331.99M)(456.68M)(493.48M)(774.83M)
EBITDA Margin-260.8%-351.0%-6064.9%-2671.2%-880.1%
Operating Income(186.31M)(324.2M)(496.21M)(536.25M)(612.26M)
Operating Margin-264.5%-342.8%-6589.7%-2902.7%-695.4%
Interest Income331K11.34M27.63M51.53M48.42M
Interest Expense29.33M51.16M57.67M86.51M103.87M
Other Income / Expenses(29M)(64.75M)(30.04M)(53.28M)(172.7M)
Income Before Tax(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Pre-Tax Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
Income Tax Expense00000
Net Income(215.31M)(388.96M)(526.24M)(589.53M)(784.96M)
Net Margin-305.7%-411.2%-6988.6%-3191.1%-891.6%
EPS (Basic)(2.80)(4.33)(5.45)(5.26)(6.54)
EPS (Diluted)(2.80)(4.33)(5.45)(5.26)(6.54)
Weighted Avg Shares76.89M89.83M96.52M111.98M120.02M
Weighted Avg Shares (Diluted)76.89M89.83M96.52M111.98M120.1M

Cytokinetics, Incorporated

NASDAQ:CYTK

Intrinsic Alpha fair value

Locked

Current Price

$51.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.